SEATTLE--(BUSINESS WIRE)--Etubics Corporation, a Seattle-based biopharmaceutical company, has announced that it has received a Small Business Innovation Research (SBIR) grant from the National Institute of Allergy and Infectious Diseases (NIAID) of the National Institutes of Health (NIH) in the amount of $600,000. The grant will be used to expand Etubics’ next generation HIV vaccine into the immune targets Pol and Nef.
